This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside

Investing in penny stocks -- companies with share prices under around $5 apiece -- could lead to monster returns over the long run. The flip side is that these corporations tend to carry above-average risk. It's challenging to determine which penny stocks might go on to deliver excellent performances and which will fade into utter insignificance.Perhaps looking at the opinion of Wall Street analysts can help. Many who cover a little-known biotech company called Iovance Biotherapeutics (NASDAQ: IOVA) are bullish on the stock. The drugmaker hit its 52-week low of $1.64 a few weeks ago, although it has rebounded somewhat since. Still, at $2.23 per share as of this writing, Iovance's average price target of $10.70 (according to Yahoo! Finance) implies an upside of almost 380%.But before you rush to purchase Iovance stock, let's dig in a little more and figure out whether it's worth your money.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool